Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 6.28%
As of Wednesday, August 19, Larimar Therapeutics, Inc.’s LRMR share price has surged by 6.28%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Commentary & Analysis
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 7.36%
As of Tuesday, August 11, Larimar Therapeutics, Inc.’s LRMR share price has surged by 7.36%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 5.49%
As of Monday, July 13, Larimar Therapeutics, Inc.’s LRMR share price has dipped by 5.49%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 5.33%
As of Friday, July 10, Larimar Therapeutics, Inc.’s LRMR share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 8.73%
As of Thursday, July 09, Larimar Therapeutics, Inc.’s LRMR share price has surged by 8.73%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $433.7 | $286.3 | 35% |
|
| Shares Out (Mil) | 104.4 | 54.2 | 63% |
|
| Institutional Ownership | 97.5% | 92.8% | 74% |
|
| Float (Mil) | 57.9 | 39.7 | 50% |
|
| Beta | 0.75 | 0.94 | 45% |
|
| Avg Daily Volume (000s) | 1,169 | 534 | 73% |
|
| Price Change (52-week) |
13.8% | 58.7% | 57% |
|
| Growth | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (31.3%) | (10.1%) | 13% |
|
| EPS (5yr) | 8.7% | 16.0% | 44 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (34.0%) | (15.6%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 8 | |
| Current EPS | ($0.349) | ($1.351) | ($1.060) | |
| Month Ago EPS | ($0.421) | ($1.607) | ($1.180) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 2 | |
| Three Months Ago EPS | ($0.430) | ($1.620) | ($1.246) | |
| Year/Year Chg | 11.1% | (40.5%) | (82.8%) | |
| Financials | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($173) | ($43) | 8% |
|
| EPS (TTM) | ($1.926) | ($1.400) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($156) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $72 | $2 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 23% |
|
| Enterprise Value (Q1) (Mil) | $278 | $160 | 29% |
|
| Valuation | LRMR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.41 | 2.77 | 68% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | LRMR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (109.5%) | (47.3%) | 5% |
|
| ROE | (139.6%) | (55.0%) | 6% |
|
| Liabilities to Assets | 22.9% | 29.6% | 15% |
|
| F-Score | 1 | 2 | 1% |
|
Larimar Therapeutics, Inc. did not pass any screens on 8/20/2026.
